




RealRate

PHARMACEUTICAL 2019

Arrowhead Pharmaceuticals INC
Rank 97 of 361



The relative strengths and weaknesses of Arrowhead Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arrowhead Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Arrowhead Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 329%, being 79% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	78,769
Cost of Goods Sold	0
Intangible Assets	18,764
Liabilities, Current	12,365
Liabilities, Non-Current	4,004
Other Assets	142
Other Compr. Net Income	-55
Other Expenses	2.4
Other Liabilities	0
Other Net Income	1,488
Other Revenues	16,142
Property and Equipment	13,935
Research and Development	52,969
Selling, General and Administrative Expense	19,110

Output Variable	Value in 1000 USD
Assets	111,610
Liabilities	16,369
Expenses	72,081
Revenues	16,142
Stockholders Equity	95,241
Net Income	-54,450
Comprehensive Net Income	-54,478
BaseVar	108,873
ECR before LimitedLiability	239%
Economic Capital Ratio	329%